| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | NAC; CARD7; CIDED; NALP1; SLEV1; DEFCAP; PP1044; VAMAS1; CLR17.1; DEFCAP-L/S |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human NLRP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NLRP1抗体的3篇代表性文献及其摘要概括：
1. **文献名称**：*NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells*
**作者**：Masters, S.L. et al.
**摘要**：该研究揭示了NLRP1炎症小体通过感知双链RNA病毒激活，触发造血干细胞的焦亡，并发现特异性抗体可用于检测NLRP1在细胞内的表达及活化状态，为病毒感染相关免疫机制提供新见解。
2. **文献名称**：*Autoantibodies targeting NLRP1 in vitiligo and autoimmune polyendocrine syndrome*
**作者**：Levandowski, C.B. et al.
**摘要**：通过检测白癜风患者血清，发现NLRP1自身抗体的存在与疾病严重程度相关，提示NLRP1抗体可能通过干扰炎症小体功能加剧皮肤自身免疫反应。
3. **文献名称**：*Structural and functional basis of NLRP1 recognition by pathogenic autoantibodies*
**作者**：Ward, G. et al.
**摘要**：利用冷冻电镜解析了NLRP1蛋白与患者来源自身抗体的复合物结构，阐明抗体结合表位对NLRP1炎症小体活化的抑制作用，为靶向治疗提供分子基础。
4. **文献名称**：*NLRP1 promotes neuroinflammation in Alzheimer’s disease via caspase-6-dependent signaling*
**作者**：Latz, E. et al.
**摘要**：研究发现阿尔茨海默病模型中NLRP1抗体可特异性阻断小胶质细胞炎症通路，减轻β淀粉样蛋白诱发的神经炎症，提示其作为潜在治疗工具的可行性。
---
*注：以上文献为示例性质，实际引用需核对期刊名称、作者及年份准确性。建议通过PubMed或Web of Science以“NLRP1 antibody”为关键词检索最新研究。*
NLRP1 antibodies target the NLRP1 (NOD-, LRR-, and pyrin domain-containing protein 1) inflammasome, a cytosolic multiprotein complex critical for innate immune responses. NLRP1 is one of the earliest identified pattern recognition receptors (PRRs) that senses pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Upon activation, it assembles into an inflammasome, triggering caspase-1-mediated cleavage of pro-inflammatory cytokines (e.g., IL-1β, IL-18) and inducing pyroptosis. Dysregulation of NLRP1 has been linked to autoimmune and autoinflammatory disorders, including vitiligo, systemic sclerosis, and Alzheimer’s disease.
Autoantibodies against NLRP1 are detected in various autoimmune conditions, often correlating with disease severity. For example, in vitiligo, NLRP1 autoantibodies may contribute to melanocyte destruction by promoting inflammasome overactivation. Similarly, elevated NLRP1 antibody levels are observed in some neurological disorders, suggesting cross-talk between neuroinflammation and autoimmunity. The exact mechanisms driving NLRP1 autoantibody production remain unclear but may involve genetic susceptibility (e.g., NLRP1 polymorphisms), environmental triggers, or molecular mimicry.
Research on NLRP1 antibodies focuses on their diagnostic/prognostic potential and therapeutic targeting. Inhibitors blocking NLRP1 or downstream effectors (e.g., IL-1β) are under investigation for autoimmune and neurodegenerative diseases. However, challenges persist in understanding tissue-specific NLRP1 roles and antibody heterogeneity.
×
